We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $8.17B
1-Year Est. Return 68.82%
This Fund
S&P 500
This Quarter Est. Return
+25.15%
1 Year Est. Return
+68.82%
3 Year Est. Return
+79.68%
5 Year Est. Return
+64.24%
10 Year Est. Return
+259.8%
AUM
$8.17B
AUM Growth
+$2.55B
Cap. Flow
+$12.3M
Cap. Flow %
0.15%
Top 10 Hldgs %
61.52%
Holding
432
New
171
Increased
73
Reduced
69
Closed
99

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$36.5M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$36.1M
3
SNY icon
Sanofi
SNY
+$34.1M
4
CYTK icon
Cytokinetics
CYTK
+$31.4M
5
WAT icon
Waters Corp
WAT
+$25.6M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$147M
2
PTCT icon
PTC Therapeutics
PTCT
+$72.4M
3
IMVT icon
Immunovant
IMVT
+$55.7M
4
DDOG icon
Datadog
DDOG
+$31.8M
5
AVNS
Avanos Medical
AVNS
+$28M

Sector Composition

Rank Sector Weight
1 Miscellaneous 55.89%
2 Healthcare 30.09%
3 Technology 6.58%
4 Consumer Discretionary 3.42%
5 Communication Services 1.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ITGR icon
76
Integer Holdings
ITGR
$4.3B
$15.7M 0.19%
+167,746
New +$14.9M
CPRI icon
77
Capri Holdings
CPRI
$1.54B
$15.5M 0.19%
836,000
+178,000
+27% +$3.42M
XERS icon
78
Xeris Biopharma Holdings
XERS
$1.56B
$15.5M 0.19%
1,958,702
+48,864
+3% +$312K
SRRK icon
79
Scholar Rock
SRRK
$6.74B
$15.3M 0.19%
278,000
-58,959
-17% -$2.85M
LYV icon
80
Live Nation Entertainment
LYV
$40.4B
$15M 0.18%
+81,824
New +$13.5M
NVO
81
Novo Nordisk
NVO
$206B
$15M 0.18%
+312,000
New +$13.4M
TWST icon
82
Twist Bioscience
TWST
$8.21B
$14.6M 0.18%
+142,000
New +$9.24M
APP icon
83
Applovin
APP
$107B
$14.5M 0.18%
28,228
+3,806
+16% +$1.84M
BCYC
84
Bicycle Therapeutics
BCYC
$301M
$14.4M 0.18%
3,398,000
– –
PENN icon
85
PENN Entertainment
PENN
$2.29B
$14.4M 0.18%
672,000
-906,000
-57% -$16.2M
BMY icon
86
Bristol-Myers Squibb
BMY
$136B
$13.5M 0.16%
233,790
+28,766
+14% +$1.65M
BBOT
87
BridgeBio Oncology
BBOT
$720M
$13.4M 0.16%
1,764,000
+436,000
+33% +$3.64M
CROX icon
88
Crocs
CROX
$5.63B
$13.4M 0.16%
111,186
-43,407
-28% -$4.74M
MU icon
89
Micron Technology
MU
$1.15T
$13.4M 0.16%
11,567
-11,726
-50% -$8.79M
BE icon
90
Bloom Energy
BE
$74.5B
$13.2M 0.16%
43,658
-4,079
-9% -$1.05M
VERA icon
91
Vera Therapeutics
VERA
$2.59B
$12.9M 0.16%
300,000
+1,836
+0.6% +$68.4K
TTWO icon
92
Take-Two Interactive
TTWO
$40.1B
$12.5M 0.15%
+49,877
New +$11M
SYRE icon
93
Spyre Therapeutics
SYRE
$7.85B
$12.2M 0.15%
137,588
+16,657
+14% +$1.22M
KYMR icon
94
Kymera Therapeutics
KYMR
$9.76B
$12.2M 0.15%
106,272
+22,396
+27% +$1.92M
VYGR icon
95
Voyager Therapeutics
VYGR
$216M
$12M 0.15%
3,436,000
-64,000
-2% -$243K
MRVL icon
96
Marvell Technology
MRVL
$201B
$11.9M 0.15%
+39,978
New +$8.02M
TER icon
97
Teradyne
TER
$55.8B
$11.9M 0.15%
24,540
-19,392
-44% -$7.31M
GNRC icon
98
Generac Holdings
GNRC
$11.1B
$11.7M 0.14%
39,924
-4,978
-11% -$1.25M
RDDT icon
99
Reddit
RDDT
$29.7B
$11.6M 0.14%
67,000
-3,000
-4% -$480K
NUVB icon
100
Nuvation Bio
NUVB
$2.39B
$11.4M 0.14%
2,000,000
+264,000
+15% +$1.29M
2 3
4
5 6

Similar funds

MWM
Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return
SC
Saturna Capital Bellingham, Washington $8.19B AUM 42.01% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
BIM
Bridges Investment Management Omaha, Nebraska $8.22B AUM 21.38% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Armistice Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Armistice Capital held 432 positions worth $8.17B, up 45% from $5.62B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Armistice Capital's Q2 2026 filing shows 171 new, 73 increased, 69 reduced and 99 closed positions. Its largest new stake was Waters Corp: 75,004 shares worth $28.1M. The largest sale was Travere Therapeutics, an estimated $147M.

By sector, the portfolio is most concentrated in Miscellaneous at 56% of assets, up from 46% a quarter earlier, followed by Healthcare and Technology.

  • Armistice Capital's largest Q2 2026 buy was Waters Corp: 75,004 shares worth $28.1M.
  • Armistice Capital added most to Regeneron Pharmaceuticals in Q2 2026, an estimated $36.5M increase.
  • Armistice Capital's biggest Q2 2026 reduction was Travere Therapeutics, cutting an estimated $147M.
  • Armistice Capital fully exited Avanos Medical in Q2 2026, selling an estimated $28M.
  • Armistice Capital's ten largest holdings make up 62% of its $8.17B portfolio in Q2 2026.
  • Armistice Capital opened 171 new positions and closed 99 in Q2 2026.
  • Armistice Capital's portfolio value rose 45% quarter-over-quarter to $8.17B.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.